Driving
CMT Research
with the
Patient’s Voice
With your help support love
nothing is impossible!
Drive Research
Drive Research
Turn your symptoms into science
Join Team CMT
Join Team CMT
Pledge Monthly
Pledge Monthly
Start your Monthly Gift of $10 today or consider the many other ways to give!
Research CMT
Research CMT
HNF has been conducting patient-focused research dating back to 2007.
Gift a Birthday
Gift a Birthday
Celebrate your birthday with a purpose! Start a Birthday CMT Fundraiser.
2025 CMT Clinical Trial Readiness Summit
April 24-26 – Reserve Your Summit Spot!
Experience the 2025 HNF CMT Summit & Wellness Retreat in Nashville, TN, April 24-26! Dive into groundbreaking research and clinical trial readiness while rejuvenating with wellness workshops, fitness activities, and community connection.
Welcome To The
Hereditary Neuropathy Foundation
Our mission is to increase awareness and accurate diagnosis of Charcot-Marie-Tooth (CMT) and related inherited neuropathies, support people living with CMT and their families with critical information to improve quality of life, and fund research that will lead to treatments and cures.
What is CMT?
Genetic Testing
Patient Resources
Pediatrics & CMT
Newsletter
Join for notifications on events, campaigns, & news
About HNF
Founded in the early 2000’s, HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD) as a collaborative effort with academia, government, and industry to develop treatments for CMT.
In accordance with the FDA’s patient-focused drug development guidance for enhancing the incorporation of the patient’s voice in medical product development and regulatory decision making, HNF has developed a regulatory strategy to support FDA Guidelines to engage with industry early on and assist with collecting and submitting robust and meaningful patient experience data, and other relevant information from patients and caregivers, such as identifying what is important to patients.
HNF is actively committed to increasing awareness and accurate diagnosis of CMT and providing patients and families with critical information to improve quality of life.
From Our Blog
LATEST
CMT Summit + Retreat 2025
CMT Summit + Retreat 2025: Uniting Patients, Researchers, Regulators, and Industry Leaders to Accelerate CMT Research Join patients, researchers, and industry leaders April 24-26 in Nashville to advance CMT research and empower wellness. The Hereditary Neuropathy...
Alesta Therapeutics Advances ALE2 to Target Rare Forms of CMT
Early preclinical research indicates that ALE2 could effectively slow or halt the progression of these debilitating symptoms, offering new hope for patients with these rare forms of CMT.
2025 HNF CMT Summit & Wellness Retreat
Experience the 2025 HNF CMT Summit & Wellness Retreat in Nashville, TN, April 24-26!
Welcome to the CMT Simplified Podcast by the HNF
CMT Simplified is here to make staying informed about Charcot-Marie-Tooth disease (CMT) easier than ever! Each 10-20 minute episode delivers: Bite-sized updates on research breakthroughs Easy-to-understand insights into treatments Empowering knowledge—on the go!...
CMT Breakthrough: FDA Grants Orphan Drug Status to NMD670
NMD670, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA)
A Recipe for CMT Treatments: Grateful for You This Thanksgiving
This Thanksgiving, we’re filled with gratitude for YOU. Your support, encouragement, and belief in our mission make everything we do at the Hereditary Neuropathy Foundation (HNF) possible. As we reflect on the progress we’ve made this year, it reminds us of a...
Update on NMD Pharma Clinical Trial
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-MarieTooth Disease Type 1 and 2 NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, announces that...
HNF’s Wearable Tech Study Delivers Strong Results for CMT Clinical Trials
HNF’s Wearable Tech Study Delivers Strong Results for CMT Clinical Trials The Hereditary Neuropathy Foundation (HNF) is breaking new ground in Charcot-Marie-Tooth (CMT) research with a pioneering study that uses wearable technology to monitor function in CMT patients....
Featured
CMT Summit + Retreat 2025
CMT Summit + Retreat 2025: Uniting Patients, Researchers, Regulators, and Industry Leaders to Accelerate CMT Research Join patients, researchers, and industry leaders April 24-26 in Nashville to advance CMT research and empower wellness. The Hereditary Neuropathy...
Alesta Therapeutics Advances ALE2 to Target Rare Forms of CMT
Early preclinical research indicates that ALE2 could effectively slow or halt the progression of these debilitating symptoms, offering new hope for patients with these rare forms of CMT.
HNF Awards the inaugural HNF Clinical Translation Fellowship
HNF Awards the inaugural HNF Clinical Translation Fellowship in the amount of $170,000 to Kayla Cornett, PhD We are thrilled to announce the establishment of the HNF Clinical Translation Fellowship, awarded to Kayla Cornett, PhD, a distinguished postdoctoral research...
Research Opportunity: CMT-SORD
Research Opportunity: CMT-SORD I am writing to you today because there is a research opportunity you may be eligible for. When you joined HNF’s Global Registry for Inherited Neuropathies (GRIN), you agreed to be contacted regarding these opportunities. Since 2001, the...
Featured Webinars
Cannabis & CMT
An insightful CMT-Connect Webinar discussing CBD and Cannabis for CMT symptoms
CMT-Connect Webinar: Surgery & CMT with Dr. Glenn Pfeffer
Dr. Glenn Pfeffer has been performing surgery on CMT patients for over 30 years crediting much of his passion to HNF’s CEO & Founder, Allison Moore
UPCOMING EVENTS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.